CLCS Stock Overview
A biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cell Source, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.31 |
| 52 Week High | US$0.84 |
| 52 Week Low | US$0.0008 |
| Beta | -195.42 |
| 1 Month Change | -7.29% |
| 3 Month Change | 0.48% |
| 1 Year Change | n/a |
| 3 Year Change | -43.36% |
| 5 Year Change | -38.92% |
| Change since IPO | -79.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLCS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.3% | 2.7% | 2.9% |
| 1Y | n/a | -6.7% | 10.0% |
Return vs Industry: Insufficient data to determine how CLCS performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CLCS performed against the US Market.
Price Volatility
| CLCS volatility | |
|---|---|
| CLCS Average Weekly Movement | 32.5% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: CLCS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLCS's weekly volatility has decreased from 7442% to 32% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1 | Itamar Shimrat | cell-source.com |
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases.
Cell Source, Inc. Fundamentals Summary
| CLCS fundamental statistics | |
|---|---|
| Market cap | US$13.47m |
| Earnings (TTM) | -US$6.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs CLCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLCS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.57m |
| Earnings | -US$6.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -53.3% |
How did CLCS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 07:09 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cell Source, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.